Can aging be cured? That’s the question that UC Santa Barbara (UCSB) startup Integrated Biosciences is trying to answer. Co-founders Felix Wong and UCSB Associate Professor Max Wilson launched the company in 2022 with the goal of finding treatments for aging itself. The startup is not seeking cures for one illness. Instead, Integrated is using machine learning to identify molecules inside aging cells. Once identified, artificial intelligence (AI) can be used to understand what is happening to the molecules and then to create drugs that will restore them. The company is targeting drugs for diverse age-associated illnesses including cancer, Alzheimer’s, and diabetes.
Integrated’s innovative platform partners synthetic biology with chemistry and AI, enabling dynamic control of biological targets and pathways. The resulting high-fidelity datasets unlock systematic exploration of previously inaccessible chemical space, and the company’s three-pronged approach to drug discovery includes hypothesis-driven research, broad screen of disease factors, and AI-powered discovery. Together, these complementary strategies allow Integrated to develop a portfolio of best-in-class age-related therapeutics.
In only a few years, Integrated has made significant progress toward its goal to end aging. In 2024, the company partnered with Illumina, a biotechnology company that develops integrated tools for genetic analysis
The partnership provides scientific support in addition to an investment. Integrated also raised $17.2M in 2024, through a seed round led by Sutter Hill Ventures. 2025 saw the launch of Integrated’s drug discovery platform, enabling precise control of the integrated stress response, and the announcement of its Scientific Advisory Board featuring world leaders in synthetic and aging biology, chemistry, and drug discovery.